Description

BioNTech’s Bold Oncology Push — Can Its Late-Stage Pipeline Unlock the Next Blockbuster Era?

BioNTech SE’s full-year and fourth-quarter 2025 update highlights a transitional period marked by stable revenue and a strategic pivot toward oncology-driven growth. Total revenue reached approximately EUR 2.9 billion, slightly higher year over year. Performance was supported by continued leadership in COVID-19 vaccines—distributed across more than 180 countries with over 50% market share in key regions—along with EUR 613 million in collaboration payments from Bristol Myers Squibb (BMS). However, COVID-19 vaccine revenue declined compared with prior years as the market shifted to an endemic phase and competition intensified, particularly in the United States and Europe. Geographic dynamics also affect results; direct sales in Germany mean revenue declines there flow directly to BioNTech’s top line, while sales in other markets are shared with Pfizer. Research and development expenses totaled about EUR 2.1 billion in 2025, slightly lower than the previous year despite advancing multiple late-stage oncology programs.